Emily Bodnar Analyst PerformanceBiotech Equity Research Analyst at HC WainwrightEmily Bodnar is a stock analyst at HC Wainwright focused in the medical sector, covering 34 publicly traded companies. Over the past year, Emily Bodnar has issued 67 stock ratings, including strong buy, buy, and hold recommendations. While full access to Emily Bodnar's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Emily Bodnar's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings117 Last 1 YearsBuy Recommendations90.60% 106 Buy RatingsCompanies Covered34 Unique Companies Ratings Distribution117RatingsDistribution of strong buy, buy, hold, and sell ratings by Emily Bodnar.RatingPercentageCount Strong Buy0.9%1 ratings Buy89.7%105 ratings Hold9.4%11 ratings Sell0.0%0 ratingsOut of 117 total stock ratings issued by Emily Bodnar at HC Wainwright, the majority (89.7%) have been Buy recommendations, followed by 9.4% Hold and 0.9% Strong Buy.Best & Worst CallsBest Call0000.0%OLMAMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%RNAZFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ97.1% of companies on NASDAQ33 companiesNYSE2.9% of companies on NYSE1 companyEmily Bodnar, an analyst at HC Wainwright, currently covers 34 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical33 companies97.1%Manufacturing1 company2.9%Emily Bodnar of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE28 companies82.4%MED - DRUGS3 companies8.8%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company2.9%BIOTECHNOLOGY1 company2.9%MED INSTRUMENTS1 company2.9% About Emily BodnarEmily Bodnar is a Vice President of Equity Research at H.C. Wainwright who joined the firm in January 2022. Ms. Bodnar’s research focuses on the Biotechnology and Women’s Healthcare industries. Prior to joining H.C. Wainwright, Ms. Bodnar was a Senior Equity Research Associate at Cantor Fitzgerald assisting in coverage of small/mid and large-cap biotechnology companies. Ms. Bodnar also worked as an Equity Research Associate at Berenberg Capital Markets assisting in coverage of small/mid-cap biotechnology companies. Ms. Bodnar graduated summa cum laude from Binghamton University where she received a Bachelor of Science. Ms. Bodnar has also taken several Biology and Immunology courses from Johns Hopkins University and Rice University.Follow on LinkedIn Emily Bodnar's Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCOAGHemab Therapeutics6/26/2026Reiterated Rating$31.42$40.00Buy$0.0000.00% ROINVCRNovoCure6/18/2026Reiterated Rating$14.68$46.00Buy$0.0000.00% ROICOAGHemab Therapeutics6/17/2026Initiated Coverage$25.51$40.00Buy$0.0000.00% ROICOAGHemab Therapeutics6/17/2026Initiated Coverage$26.45$40.00Buy$0.0000.00% ROISABSSAB Biotherapeutics6/15/2026Reiterated Rating$3.33$10.00Buy$0.0000.00% ROITGTXTG Therapeutics5/27/2026Reiterated Rating$39.76$70.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals5/22/2026Reiterated Rating$14.06Buy$0.0000.00% ROIINKTMiNK Therapeutics5/18/2026Reiterated Rating$10.48$35.00Buy$0.0000.00% ROIAUTLAutolus Therapeutics5/14/2026Boost Price Target$1.59$10.00Buy$0.0000.00% ROISABSSAB Biotherapeutics5/12/2026Boost Price Target$3.60$10.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ARTVArtiva Biotherapeutics5/8/2026Boost Price Target$11.85$35.00Buy$0.0000.00% ROITGTXTG Therapeutics5/6/2026Boost Price Target$39.69$70.00Buy$0.0000.00% ROITRAXFirst Tracks Biotherapeutics4/28/2026Initiated Coverage$18.10$30.00Buy$0.0000.00% ROITRAXFirst Tracks Biotherapeutics4/28/2026Upgrade$20.05$30.00Strong-Buy$0.0000.00% ROIAGIOAgios Pharmaceuticals4/20/2026Lower Price Target$27.11$50.00Buy$0.0000.00% ROIINKTMiNK Therapeutics4/1/2026Reiterated Rating$10.53$35.00Buy$0.0000.00% ROIANABAnaptysBio3/30/2026Reiterated Rating$57.40$66.00Buy$0.0000.00% ROIATOSAtossa Genetics3/26/2026Boost Price Target$5.42$25.00Buy$0.0000.00% ROIPPBTPurple Biotech3/13/2026Lower Price Target$4.10$30.00Buy$0.0000.00% ROISABSSAB Biotherapeutics3/10/2026Lower Price Target$3.84$7.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals3/9/2026Lower Price Target$17.25$38.00Buy$0.0000.00% ROISANASana Biotechnology3/4/2026Lower Price Target$3.93$7.00Buy$0.0000.00% ROIANABAnaptysBio3/4/2026Boost Price Target$52.83$66.00Buy$0.0000.00% ROIRCUSArcus Biosciences3/2/2026Reiterated Rating$20.36$32.00Buy$0.0000.00% ROINVCRNovoCure2/26/2026Boost Price Target$13.11$49.00Buy$0.0000.00% ROIACLXArcellx2/23/2026Downgrade$113.84$115.00Neutral$0.0000.00% ROIAUTLAutolus Therapeutics2/17/2026Initiated Coverage$1.40$9.00Buy$0.0000.00% ROIAUTLAutolus Therapeutics2/17/2026Initiated Coverage$1.51$9.00Buy$0.0000.00% ROINVCRNovoCure2/12/2026Boost Price Target$10.50$47.00Buy$0.0000.00% ROIAGIOAgios Pharmaceuticals2/12/2026Boost Price Target$28.71$65.00Buy$0.0000.00% ROIACLXArcellx2/4/2026Reiterated Rating$68.83$115.00Buy$0.0000.00% ROIRAPTRapt Therapeutics1/20/2026Downgrade$57.52$58.00Neutral$0.0000.00% ROINVCRNovoCure1/13/2026Lower Price Target$14.18$39.00Buy$0.0000.00% ROIVTYXVentyx Biosciences1/8/2026Downgrade$13.73$14.00Neutral$0.0000.00% ROIAGIOAgios Pharmaceuticals12/24/2025Boost Price Target$28.85$62.00Buy$0.0000.00% ROIVTVTvTv Therapeutics12/19/2025Reiterated Rating$34.72$47.00Buy$0.0000.00% ROIRCUSArcus Biosciences12/12/2025Boost Price Target$22.39$32.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals12/11/2025Boost Price Target$30.68$45.00Buy$0.0000.00% ROIACRVAcrivon Therapeutics11/25/2025Reiterated Rating$2.36$19.00Buy$0.0000.00% ROIANABAnaptysBio11/24/2025Lower Price Target$39.61$51.00Buy$0.0000.00% ROIThe $15 Gold Fund That Pays Up to $1,152/Month (Ad)Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.Discover the gold income fund before the next payout dateAGIOAgios Pharmaceuticals11/20/2025Lower Price Target$22.34$48.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals11/18/2025Boost Price Target$19.85$36.00Buy$0.0000.00% ROIARTVArtiva Biotherapeutics11/12/2025Boost Price Target$3.65$15.00Buy$0.0000.00% ROIANABAnaptysBio11/11/2025Lower Price Target$33.98$52.00Buy$0.0000.00% ROISANASana Biotechnology11/7/2025Lower Price Target$4.05$9.00Buy$0.0000.00% ROICNTXContext Therapeutics11/6/2025Boost Price Target$1.13$5.00Buy$0.0000.00% ROIVTYXVentyx Biosciences11/5/2025Upgrade$8.09$18.00Buy$0.0000.00% ROINVCRNovoCure10/30/2025Boost Price Target$12.79$42.00Buy$0.0000.00% ROIRCUSArcus Biosciences10/29/2025Boost Price Target$19.89$28.00Buy$0.0000.00% ROIRAPTRapt Therapeutics10/27/2025Boost Price Target$30.11$72.00Buy$0.0000.00% ROIAGENAgenus10/20/2025Reiterated Rating$3.88Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals10/20/2025Reiterated Rating$9.36$28.00Buy$0.0000.00% ROISNTISenti Biosciences10/14/2025Initiated Coverage$1.68$12.00Buy$0.0000.00% ROITGTXTG Therapeutics10/6/2025Initiated Coverage$36.71$60.00Buy$0.0000.00% ROITGTXTG Therapeutics10/6/2025Initiated Coverage$36.76$60.00Buy$0.0000.00% ROIANABAnaptysBio9/30/2025Boost Price Target$23.27$59.00Buy$0.0000.00% ROIIOBTIO Biotech9/29/2025Downgrade$0.35Neutral$0.0000.00% ROIAGENAgenus9/10/2025Reiterated Rating$5.07$23.00Buy$0.0000.00% ROIAGIOAgios Pharmaceuticals9/4/2025Reiterated Rating$35.90$56.00Buy$0.0000.00% ROIAGENAgenus8/28/2025Reiterated Rating$4.54$23.00Buy$0.0000.00% ROIINKTMiNK Therapeutics8/15/2025Upgrade$15.32$35.00Buy$0.0000.00% ROIVTVTvTv Therapeutics8/13/2025Reiterated Rating$14.50$36.00Buy$0.0000.00% ROIFEMYFemasys8/11/2025Lower Price Target$16.94$160.00Buy$0.0000.00% ROICNTXContext Therapeutics8/7/2025Lower Price Target$0.70$4.00Buy$0.0000.00% ROISABSSAB Biotherapeutics7/22/2025Lower Price Target$2.70$9.00Buy$0.0000.00% ROIINKTMiNK Therapeutics7/15/2025Downgrade$29.53$35.00Neutral$0.0000.00% ROIJSPRJasper Therapeutics7/7/2025Lower Price Target$3.04$20.00Buy$0.0000.00% ROINXTCNextCure7/1/2025Reiterated Rating$5.52$36.00Buy$0.0000.00% ROIFEMYFemasys6/25/2025Reiterated Rating$19.00$240.00Buy$0.0000.00% ROIACLXArcellx6/16/2025Reiterated Rating$66.00$115.00Buy$0.0000.00% ROIFEMYFemasys6/11/2025Reiterated Rating$16.74$240.00Buy$0.0000.00% ROIAGENAgenus6/4/2025Upgrade$5.00$25.00Buy$0.0000.00% ROISABSSAB Biotherapeutics5/14/2025Initiated Coverage$1.80$10.00Buy$0.0000.00% ROIAGENAgenus5/13/2025Reiterated Rating$3.50Neutral$0.0000.00% ROIFEMYFemasys5/9/2025Lower Price Target$23.20$240.00Buy$0.0000.00% ROIAGENAgenus4/30/2025Reiterated Rating$3.05Neutral$0.0000.00% ROIOLMAOlema Pharmaceuticals4/28/2025Reiterated Rating$4.91$30.00Buy$00.0000.00% ROISANASana Biotechnology4/24/2025Reiterated Rating$1.71$11.00Buy$0.0000.00% ROIBCTXBriacell Therap4/22/2025Reiterated Rating$48.03$320.00Buy$0.0000.00% ROIRNAZTransCode Therapeutics4/16/2025Lower Price Target$11.14$280.00Buy$0.0000.00% ROIVTVTvTv Therapeutics4/9/2025Initiated Coverage$15.80$36.00Buy$00.0000.00% ROIIOBTIO Biotech4/1/2025Reiterated Rating$1.09$12.00Buy$0.0000.00% ROIGNLXGenelux3/31/2025Reiterated Rating$3.08$30.00Buy$0.0000.00% ROICNTBConnect Biopharma3/31/2025Reiterated Rating$0.68$8.00Buy$0.0000.00% ROIFEMYFemasys3/28/2025Reiterated Rating$26.70$300.00Buy$0.0000.00% ROINKTXNkarta3/27/2025Reiterated Rating$1.37$18.00Buy$0.0000.00% ROIIMNNImunon3/26/2025Reiterated Rating$15.00$210.00Buy$0.0000.00% ROIACRVAcrivon Therapeutics3/26/2025Lower Price Target$5.39$19.00Buy$0.0000.00% ROIATOSAtossa Genetics3/26/2025Reiterated Rating$10.86$105.00Buy$0.0000.00% ROIGNLXGenelux3/25/2025Reiterated Rating$3.41$30.00Buy$0.0000.00% ROIUrgent exposé on the "Mar-a-Lago Trade" (Ad)Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent exposé on what he calls the $7.2 trillion 'Mar-a-Lago Trade.' Bloomberg warns it may cause 'a dire shift of fortunes for America.' Eifrig, who called the 2022 crash months early, says this event is already underway and could move as high as 10x from current levels. Over 500,000 paid subscribers follow his research. Access the full free broadcast before it comes down.Watch Dr. Eifrig's free broadcast and get the full story nowCNTXContext Therapeutics3/21/2025Reiterated Rating$0.77$5.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals3/19/2025Reiterated Rating$4.14$30.00Buy$00.0000.00% ROIFEMYFemasys3/19/2025Boost Price Target$31.92$300.00Buy$00.0000.00% ROIAGENAgenus3/18/2025Reiterated Rating$1.78Neutral$0.0000.00% ROISANASana Biotechnology3/18/2025Reiterated Rating$2.77$11.00Buy$0.0000.00% ROIINKTMiNK Therapeutics3/18/2025Reiterated Rating$8.06$35.00Buy$0.0000.00% ROINXTCNextCure3/17/2025Reiterated Rating$8.45$36.00Buy$00.0000.00% ROIRNAZTransCode Therapeutics3/13/2025Reiterated Rating$25.34$560.00Buy$0.0000.00% ROIFEMYFemasys3/13/2025Reiterated Rating$28.80$240.00Buy$00.0000.00% ROIATOSAtossa Genetics3/12/2025Reiterated Rating$11.11$105.00Buy$0.0000.00% ROIAGENAgenus3/12/2025Reiterated Rating$2.05Neutral$0.0000.00% ROIOLMAOlema Pharmaceuticals3/11/2025Reiterated Rating$4.25$30.00Buy$00.0000.00% ROIJSPRJasper Therapeutics3/11/2025Reiterated Rating$5.14$40.00Buy$0.0000.00% ROINXTCNextCure3/7/2025Reiterated Rating$8.55$36.00Buy$00.0000.00% ROIIOBTIO Biotech3/5/2025Reiterated Rating$0.91$12.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals3/5/2025Reiterated Rating$4.18$30.00Buy$00.0000.00% ROIFEMYFemasys2/26/2025Reiterated Rating$31.60$240.00Buy$00.0000.00% ROIINKTMiNK Therapeutics2/25/2025Boost Price Target$10.65$35.00Buy$00.0000.00% ROIAGIOAgios Pharmaceuticals2/24/2025Initiated Coverage$35.22$58.00Buy$00.0000.00% ROIFEMYFemasys2/11/2025Reiterated Rating$25.10$240.00Buy$00.0000.00% ROIRNAZTransCode Therapeutics2/6/2025Reiterated Rating$321.02$560.00Buy$0.0000.00% ROITNYATenaya Therapeutics2/3/2025Reiterated Rating$1.05$18.00Buy$0.0000.00% ROIBCTXBriacell Therap2/3/2025Boost Price Target$50.80$320.00Buy$0.0000.00% ROIATOSAtossa Genetics1/30/2025Reiterated Rating$12.84$105.00Buy$0.0000.00% ROIAGENAgenus1/22/2025Reiterated Rating$3.83Neutral$0.0000.00% ROIVTYXVentyx Biosciences1/14/2025Reiterated Rating$1.95Neutral$00.0000.00% ROIJSPRJasper Therapeutics1/10/2025Lower Price Target$6.99$40.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftStifel Nicolaus Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.